Nkarta updates clinical progress of car-nk cell therapy nkx101 for patients with relapsed or refractory acute myeloid leukemia

South san francisco, calif., june 27, 2023 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies, today announced positive updated data from its phase 1 study of nkx101 to treat patients with relapsed or refractory (r/r) acute myeloid leukemia (aml). nkx101 is an allogeneic, off-the-shelf cell therapy candidate comprising nk cells derived from healthy donors and engineered to target nkg2d ligands on cancer cells.
NKTX Ratings Summary
NKTX Quant Ranking